From the publishers of JADPRO

HR+ HER2- Breast Cancer Resource Center

Advertisement

Cancer Treatment Reviews

First versus second-generation molecular profiling tests: How both can guide decision-making in early-stage hormone-receptor positive breast cancers?

npj Precision Oncology

Successful unconventional precision treatment of inflammatory hormone receptor-positive breast cancer guided by molecular profiling

BMC Women’s Health

Comparison of the efficacy and safety of docetaxel plus capecitabine versus docetaxel plus epirubicin for human epidermal growth factor 2 -negative breast cancer: A meta-analysis

The Breast

Awareness of genomic testing among patients with breast cancer in Europe

Breast Cancer Research and Treatment

PTEN inactivating mutations are associated with hormone receptor loss during breast cancer recurrence

Cancer Cell

CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety

Chinese Journal of Cancer Research

Clinicopathological and molecular features of HR + /HER2 - breast cancer patients with distinct endocrine resistance patterns

European Journal of Nuclear Medicine and Molecular Imaging

Predictive and prognostic value of 18F-FES PET/CT for patients with recurrent or metastatic breast cancer treated with endocrine therapy plus cyclin-dependent kinase 4/6 inhibitors

Future Oncology

Real-world study of patients with HR+/ HER2- metastatic breast cancer treated with palbociclib and fulvestrant

Cancer Letters

TFAP2C-DDR1 axis regulates resistance to CDK4/6 inhibitor in breast cancer

European Journal of Cancer

Metastasis-directed stereotactic radiotherapy and systemic treatment continuation for patients with oligoprogressive metastatic breast cancer

Journal of Cachexia, Sarcopenia, and Muscle

Low skeletal muscle radiodensity predicts response to CDK4/6 inhibitors plus aromatase inhibitors in advanced breast cancer

Nature Communications

Lerociclib plus fulvestrant in patients with HR+/HER2- locally advanced or metastatic breast cancer who have progressed on prior endocrine therapy: LEONARDA-1 a phase III randomized trial

Drugs

Efficacy and safety of CDK4/6 inhibitors: A focus on HR+/HER2- early breast cancer

Journal of Clinical Oncology

Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer: Primary results from TROPION-Breast01

U.S. Food and Drug Administration

FDA approves datopotamab deruxtecan-dlnk for unresectable or metastatic, HR-positive, HER2-negative breast cancer

Therapeutic Advances in Medical Oncology

Elacestrant plus alpelisib in an ESR1 and PIK3CA co-mutated and heavily pretreated metastatic breast cancer: The first case report for combination efficacy and safety

The Journal of Pathology. Clinical Research

High chromosomal instability is associated with higher 10-year risks of recurrence for hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients: Clinical evidence from a large-scale, multiple-site, retrospective study

Clinical Breast Cancer

Real world evidence study to assess incidence, treatment patterns, clinical outcomes, and health care resource utilization in early-stage, high-risk HER2-negative breast cancer in Alberta, Canada

Oncology Research and Treatment

Palbociclib in combination with either aromatase inhibitors or fulvestrant for patients with advanced HR+/HER2- breast cancer in Germany: Final results of the phase 2 multicohort INGE-B trial

Therapeutic Advances in Medical Oncology

Everolimus treatment in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative advanced breast cancer and a predictive model for its efficacy: A multicenter real-world study

Cureus

Dormancy leading to late recurrence in breast cancer: A case of hormone receptor-positive supraclavicular metastasis 10 years after the initial treatment

Frontiers in Immunology

Advances in Trop-2 targeted antibody-drug conjugates for breast cancer: Mechanisms, clinical applications, and future directions

Clinical Cancer Research

Hormone receptor positive HER2-negative/MammaPrint high-2 breast cancers closely resemble triple negative breast cancers

Cancer Medicine

PIK3CA mutational status in tissue and plasma as a prognostic biomarker in HR+/HER2- breast cancer

International Immunopharmacology

Pirfenidone inhibits CCL2-mediated Treg chemotaxis induced by palbociclib and fulvestrant in HR+/HER2- breast cancer

Current Medical Research and Opinion

Cost-effectiveness of CDK4/6 inhibitors in HR+/HER2− metastatic breast cancer: A systematic review and meta-analysis

ESMO Open

Real-world treatment patterns and outcomes in patients with HR+/HER2- metastatic breast cancer treated with chemotherapy in the United States

Oncology Letters

First-line endocrine therapy for hormone receptor positive and HER 2 negative metastatic breast cancer: A Bayesian network meta analysis

Translational Oncology

Excavating regulated cell death signatures to predict prognosis, tumor microenvironment and therapeutic response in HR+/HER2- breast cancer

Frontiers in Immunology

Efficacy and safety of different regimens of neoadjuvant therapy in patients with hormone receptor-positive, HER2-negative breast cancer: A network meta-analysis

American Journal of Clinical Oncology

Efficacy and safety of abemaciclib in combination with endocrine therapy for HR+/HER2- advanced or metastatic breast cancer: A systematic review and meta-analysis

JHEP Reports

CDK4/6 inhibitor-induced liver injury: Clinical phenotypes and role of corticosteroid treatment

npj Breast Cancer

A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancer

JAMA Surgery

Electronic health record-based nudge intervention and axillary surgery in older women with breast cancer: A nonrandomized controlled trial

Future Oncology

The NEOLETRIB trial: Neoadjuvant treatment with letrozole and ribociclib in ER-positive, HER2-negative breast cancer

Anticancer Research

Risk factors for non-sentinel lymph node metastasis in HR+/HER2- breast cancer with cN0

Radiology Case Reports

Palbociclib and fulvestrant combined regimen induced prolonged bone metastasis control of stage IV HR+/HER2- breast cancer: A case report

Reviews in Cardiovascular Medicine

Risk of cardiovascular events with cyclin-dependent kinases 4 and 6 (CDK 4/6) inhibitors among patients with advanced breast cancer: A systematic review and network meta-analysis

Oncology and Therapy

Palbociclib in HR-positive, HER2-negative advanced/metastatic breast cancer: A systematic scoping review of real-world evidence from countries outside of Western regions that are underrepresented in clinical trials

Journal of Clinical Medicine

Novel treatment strategies for hormone receptor (HR)-positive, HER2-negative metastatic breast cancer

Cancers (Basel)

Social determinants of health and other predictors in initiation of treatment with CDK4/6 inhibitors for HR+/HER2- metastatic breast cancer

Current Opinion in Oncology

Controversies on chemotherapy for early HR+/HER2- breast cancer: The role of anthracyclines and dose intensification

npj Breast Cancer

Impact of dose reductions on adjuvant abemaciclib efficacy for patients with high-risk early breast cancer: analyses from the monarchE study

Genetic Testing and Risk Intervention Based on Family History of Early-Onset Breast Cancer

First-Line Treatment for Metastatic ER+ HER2- Breast Cancer